MX9701327A - Methods of inhibiting endometrial cancer. - Google Patents
Methods of inhibiting endometrial cancer.Info
- Publication number
- MX9701327A MX9701327A MX9701327A MX9701327A MX9701327A MX 9701327 A MX9701327 A MX 9701327A MX 9701327 A MX9701327 A MX 9701327A MX 9701327 A MX9701327 A MX 9701327A MX 9701327 A MX9701327 A MX 9701327A
- Authority
- MX
- Mexico
- Prior art keywords
- endometrial cancer
- methods
- inhibiting endometrial
- inhibiting
- hexamethyleneimino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
A method of inhibiting endometrial cancer comprising administering to a human in need thereof an effective amount of a compound having formula (I) wherein R1 and R3 are independently hydrogen, -CH3, (a), or (b), wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29385394A | 1994-08-22 | 1994-08-22 | |
PCT/US1995/010651 WO1996005833A1 (en) | 1994-08-22 | 1995-08-21 | Methods of inhibiting endometrial cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9701327A true MX9701327A (en) | 1997-05-31 |
Family
ID=23130867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9701327A MX9701327A (en) | 1994-08-22 | 1995-08-21 | Methods of inhibiting endometrial cancer. |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0777476A4 (en) |
JP (1) | JPH10504824A (en) |
KR (1) | KR970705387A (en) |
AU (1) | AU688112B2 (en) |
CA (1) | CA2198119A1 (en) |
CZ (1) | CZ51897A3 (en) |
FI (1) | FI970717A (en) |
HU (1) | HUT76890A (en) |
IL (1) | IL115022A (en) |
MX (1) | MX9701327A (en) |
MY (1) | MY113757A (en) |
NO (1) | NO970783L (en) |
NZ (1) | NZ292017A (en) |
RU (1) | RU2161964C2 (en) |
TW (1) | TW404834B (en) |
WO (1) | WO1996005833A1 (en) |
ZA (1) | ZA956994B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856340A (en) * | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Method of treating estrogen dependent cancers |
US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
KR20160066490A (en) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | Heterocyclic derivatives and use thereof |
CN115825414B (en) * | 2023-01-09 | 2023-04-25 | 中国医学科学院北京协和医院 | Blood or urine metabolic marker and application thereof in endometrial cancer early screening |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
JP3157882B2 (en) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | New benzothiophene derivatives |
US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
JPH08512197A (en) * | 1993-04-07 | 1996-12-24 | リガンド・ファーマシューティカルズ・インコーポレーテッド | Method for screening receptor agonist |
IL111287A0 (en) * | 1993-10-15 | 1994-12-29 | Lilly Co Eli | Methods for treating resistant neoplasms |
WO1996005832A1 (en) * | 1994-08-22 | 1996-02-29 | Eli Lilly And Company | Methods of inhibiting primary endometrial hyperplasia |
US5843964A (en) * | 1994-09-22 | 1998-12-01 | Eli Lilly And Company | Methods of inhibiting endometrial mitoses |
-
1995
- 1995-08-21 IL IL11502295A patent/IL115022A/en not_active IP Right Cessation
- 1995-08-21 TW TW084108700A patent/TW404834B/en not_active IP Right Cessation
- 1995-08-21 MX MX9701327A patent/MX9701327A/en unknown
- 1995-08-21 RU RU97104160/14A patent/RU2161964C2/en active
- 1995-08-21 NZ NZ292017A patent/NZ292017A/en unknown
- 1995-08-21 JP JP8508265A patent/JPH10504824A/en active Pending
- 1995-08-21 AU AU33700/95A patent/AU688112B2/en not_active Ceased
- 1995-08-21 HU HU9701499A patent/HUT76890A/en unknown
- 1995-08-21 MY MYPI95002449A patent/MY113757A/en unknown
- 1995-08-21 KR KR1019970701095A patent/KR970705387A/en not_active Application Discontinuation
- 1995-08-21 CZ CZ97518A patent/CZ51897A3/en unknown
- 1995-08-21 WO PCT/US1995/010651 patent/WO1996005833A1/en not_active Application Discontinuation
- 1995-08-21 CA CA002198119A patent/CA2198119A1/en not_active Abandoned
- 1995-08-21 ZA ZA9506994A patent/ZA956994B/en unknown
- 1995-08-21 EP EP95930243A patent/EP0777476A4/en not_active Withdrawn
-
1997
- 1997-02-20 FI FI970717A patent/FI970717A/en unknown
- 1997-02-20 NO NO970783A patent/NO970783L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU688112B2 (en) | 1998-03-05 |
IL115022A (en) | 2000-07-31 |
FI970717A0 (en) | 1997-02-20 |
AU3370095A (en) | 1996-03-14 |
NO970783D0 (en) | 1997-02-20 |
MY113757A (en) | 2002-05-31 |
CA2198119A1 (en) | 1996-02-29 |
TW404834B (en) | 2000-09-11 |
JPH10504824A (en) | 1998-05-12 |
ZA956994B (en) | 1997-02-21 |
WO1996005833A1 (en) | 1996-02-29 |
NO970783L (en) | 1997-02-20 |
EP0777476A1 (en) | 1997-06-11 |
KR970705387A (en) | 1997-10-09 |
HUT76890A (en) | 1997-12-29 |
EP0777476A4 (en) | 1999-06-23 |
FI970717A (en) | 1997-02-20 |
RU2161964C2 (en) | 2001-01-20 |
NZ292017A (en) | 2000-07-28 |
CZ51897A3 (en) | 1997-06-11 |
IL115022A0 (en) | 1998-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9701329A (en) | Methods of inhibiting viral replication. | |
MX9701325A (en) | Methods of inhibiting ulcerative mucositis. | |
AU7578794A (en) | Methods for inhibiting endometriosis | |
MX9701360A (en) | Methods of inhibiting demyelinating and dysmyelinating diseases. | |
MX9701334A (en) | Methods for inhibiting bone prosthesis degeneration. | |
MX9709466A (en) | Methods of inhibiting melanoma. | |
MX9701327A (en) | Methods of inhibiting endometrial cancer. | |
MX9702148A (en) | Methods of inhibiting endometrial mitoses. | |
MX9701333A (en) | Methods for inhibiting neuronal damage. | |
MY113406A (en) | Methods of inhibiting physiological conditions associated with an excess of bradykinin | |
MX9701332A (en) | Methods for bone healing and fracture repair. | |
MX9701359A (en) | Methods of inhibiting primary endometrial hyperplasia. | |
MX9701331A (en) | Methods of maintaining teeth and oral bone. | |
MX9701328A (en) | Methods of reducing scarring in wound healing. | |
MX9705940A (en) | Methods of inhibiting effects of il-6 | |
MX9706520A (en) | Methods of inhibiting ovarian cancer. | |
MX9706072A (en) | Methods of inhibiting cell-cell adhesion. | |
MX9709536A (en) | Methods of inducing bef-1 transcription factor. | |
MX9705215A (en) | Methods of inhibiting growth hormone effects. | |
MX9806036A (en) | Methods of inhibiting colon tumors. | |
MX9705537A (en) | Methods of inhibiting environmental estrogens. | |
MX9709651A (en) | METHODS OF MODULATING NF-kB TRANSCRIPTION FACTOR. | |
MX9705697A (en) | Methods of decreasing serum calcium levels. | |
MX9702853A (en) | Methods of inhibiting conditions associated with neuropeptide y. |